Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC

NCT05584137 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Due to poor clinical trial accrual, the study was terminated.

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: HLX26
DRUG: HLX10

Sponsor

Shanghai Henlius Biotech